AU2022260860A1 - Novel compositions and methods for treating coronavirus infections - Google Patents

Novel compositions and methods for treating coronavirus infections Download PDF

Info

Publication number
AU2022260860A1
AU2022260860A1 AU2022260860A AU2022260860A AU2022260860A1 AU 2022260860 A1 AU2022260860 A1 AU 2022260860A1 AU 2022260860 A AU2022260860 A AU 2022260860A AU 2022260860 A AU2022260860 A AU 2022260860A AU 2022260860 A1 AU2022260860 A1 AU 2022260860A1
Authority
AU
Australia
Prior art keywords
ace2
amino acid
sars
cov
proteinaceous molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022260860A
Other languages
English (en)
Inventor
Sudha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901169A external-priority patent/AU2021901169A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of AU2022260860A1 publication Critical patent/AU2022260860A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022260860A 2021-04-20 2022-04-20 Novel compositions and methods for treating coronavirus infections Pending AU2022260860A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021901169 2021-04-20
AU2021901169A AU2021901169A0 (en) 2021-04-20 Novel compositions and methods for treating coronavirus infections
AU2022900358A AU2022900358A0 (en) 2022-02-18 Novel compositions and methods for treating coronavirus infections
AU2022900358 2022-02-18
PCT/AU2022/050363 WO2022221920A1 (en) 2021-04-20 2022-04-20 Novel compositions and methods for treating coronavirus infections

Publications (1)

Publication Number Publication Date
AU2022260860A1 true AU2022260860A1 (en) 2023-12-07

Family

ID=83723477

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022260860A Pending AU2022260860A1 (en) 2021-04-20 2022-04-20 Novel compositions and methods for treating coronavirus infections

Country Status (8)

Country Link
US (1) US20240352072A1 (https=)
EP (1) EP4326757A4 (https=)
JP (1) JP2024516605A (https=)
KR (1) KR20240027579A (https=)
AU (1) AU2022260860A1 (https=)
CA (1) CA3216329A1 (https=)
IL (1) IL307872A (https=)
WO (1) WO2022221920A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020646A1 (en) * 2022-07-27 2024-02-01 The Council Of The Queensland Institute Of Medical Research Methylation biomarker for infection resistance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2002012471A2 (en) * 2000-08-09 2002-02-14 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and uses therefor
WO2007030937A2 (en) * 2005-09-16 2007-03-22 Institut De Recherches Cliniques De Montreal/I.R.C.M. Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
CA2652247C (en) * 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
US20230152316A1 (en) * 2020-03-19 2023-05-18 Massachusetts Institute Of Technology Sars-cov2 spike protein binding peptides
WO2021195723A1 (en) * 2020-04-03 2021-10-07 The Council Of The Queensland Institute Of Medical Research "methods for treatment of coronavirus infections"
CA3179872A1 (en) * 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
CN111920806B (zh) * 2020-07-14 2023-01-03 中日友好医院(中日友好临床医学研究所) 苹果酸舒尼替尼在制备抑制冠状病毒的药物中的应用
WO2022075921A1 (en) * 2020-10-08 2022-04-14 Hummingbird Bioscience Holdings Limited Sars-cov-2 spike protein antigen-binding molecules

Also Published As

Publication number Publication date
CA3216329A1 (en) 2022-10-27
US20240352072A1 (en) 2024-10-24
KR20240027579A (ko) 2024-03-04
WO2022221920A1 (en) 2022-10-27
IL307872A (en) 2023-12-01
JP2024516605A (ja) 2024-04-16
EP4326757A1 (en) 2024-02-28
EP4326757A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
US11364276B2 (en) Antiviral peptides for treatment of the middle east respiratory syndrome
US20240218059A1 (en) TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2
EP4326757A1 (en) Novel compositions and methods for treating coronavirus infections
CN109593123B (zh) 一种衍生自rps23rg1的多肽及其应用
CN117677631A (zh) 用于治疗冠状病毒感染的新型组合物和方法
US20220242932A1 (en) Ulinastatin polypeptides for treating diseases
CN116075298B (zh) 用于治疗冠状病毒感染的方法
KR102628158B1 (ko) 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
US11376306B2 (en) Peptides and uses therefor as antiviral agents
CA2858957C (en) Modified peptides and their use for treating autoimmune diseases
JP2023546383A (ja) アネキシンａ５組成物及び方法
US20240002437A1 (en) Compositions and methods of treating inflammatory lung diseases
WO2022203981A1 (en) K-ras inhibitor
CN113150107A (zh) 一种白细胞介素29突变体蛋白
CN115667291B (zh) 一种白细胞介素29突变体蛋白
JP7185874B2 (ja) 抗ウイルス剤としてのラビリントペプチン
WO2015192223A1 (en) Peptide inhibitors of respiratory syncytial virus replication
HK40083738A (en) Soluble ace2 and fusion protein, and applications thereof
WO2022066798A1 (en) Interferon tau fc-fusion proteins and methods for treating coronavirus infections